eISSN (Online): 2598-0580



Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

The Prognostic Utility of Immature Platelet Fraction (IPF) in Adult Sepsis: A Correlation Analysis with SOFA Score and Conventional Platelet Indices

Nico Dana Saputra[1]*, Ricke Loesnihari[1], Tasrif Hamdi[2]

[1]Department of Clinical Pathology, Faculty of Medicine, Universitas Sumatera Utara/H. Adam Malik General Hospital, Medan, Indonesia

[2]Department of Anesthesiology and Intensive Therapy, Faculty of Medicine, Universitas Sumatera Utara/H. Adam Malik General Hospital, Medan, Indonesia

ARTICLE INFO

Keywords:
Futile thrombopoiesis
Immature platelet fraction
Platelet indices
Sepsis
SOFA score

***Corresponding author:**
Nico Dana Saputra

E-mail address:
dr.nicods88@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/bsm.v9i10.1419

A B S T R A C T

Background: Sepsis is a leading cause of mortality, driving the search for biomarkers that can accurately reflect its severity. The immature platelet fraction (IPF) measures real-time thrombopoiesis, which is profoundly stressed during sepsis. Its clinical utility relative to conventional platelet indices (MPV, PDW) in predicting organ dysfunction remains to be fully elucidated. This study aimed to explore the relationship between these platelet parameters and the Sequential Organ Failure Assessment (SOFA) score in adult sepsis patients. **Methods:** An observational, cross-sectional study was conducted on 32 adult patients diagnosed with sepsis at a tertiary hospital in Medan, Indonesia. Upon admission, platelet indices and IPF were measured using a Sysmex XN-1000 hematology analyzer. The SOFA score was calculated to quantify organ dysfunction. The relationships between variables were assessed using Pearson or Spearman correlation analysis. **Results:** The analysis revealed a statistically significant but weak positive correlation between IPF and the SOFA score ($r=0.354$, $p=0.047$). In contrast, conventional indices like MPV ($r=0.219$, $p=0.228$) and PDW ($r=0.190$, $p=0.297$) showed no significant association with the SOFA score. Mechanistically, strong positive correlations were confirmed between IPF and both MPV ($r=0.768$, $p<0.001$) and PDW ($r=0.775$, $p<0.001$), reflecting a coordinated bone marrow response. **Conclusion:** This study reveals a critical paradox in sepsis: while the bone marrow mounts a robust thrombopoietic response, evidenced by the tight correlation between markers of platelet production, this response is poorly coupled with clinical outcomes. The weak association between IPF and organ dysfunction severity suggests that IPF's primary utility may not be as a standalone prognostic tool, but rather as a biomarker of a high-turnover, "futile thrombopoiesis." This highlights the complexity of platelet kinetics in sepsis and warrants further investigation into its role within a multi-marker prognostic strategy.

1. Introduction

Sepsis, a syndrome of life-threatening organ dysfunction precipitated by a dysregulated host response to infection, remains one of the most formidable challenges in contemporary medicine.[1] It is a leading cause of death in intensive care units (ICUs) and imposes a staggering burden on healthcare systems worldwide through high mortality, prolonged morbidity, and immense resource consumption. The pathophysiology of sepsis is not a simple linear process but a devastatingly complex and interconnected web of events.[2] It involves a systemic inflammatory cascade, profound derangements in the coagulation system, widespread endothelial cell injury, and a subsequent spiral into multiple organ failure. The imperative for accurate and timely risk

stratification in patients with sepsis is therefore absolute; the ability to identify individuals destined for clinical deterioration is fundamental to guiding aggressive, life-saving interventions. The Sequential (Sepsis-related) Organ Failure Assessment (SOFA) score is the universally accepted gold standard for quantifying the severity of organ dysfunction and for prognosticating outcomes in sepsis.[3] While robust, its utility is constrained by its reliance on multiple clinical and laboratory inputs that may not be available in the immediate moments after a patient's presentation, potentially delaying a full risk assessment. This has spurred a relentless search for more accessible, rapid, and cost-effective biomarkers. However, the era of seeking a single "magic bullet" biomarker is largely behind us. The modern clinical challenge is to identify markers that provide unique, orthogonal information about specific pathophysiological axes, thereby complementing the existing panel of biomarkers such as lactate (for tissue perfusion) and procalcitonin (for bacterial inflammation).[4]

One of the most profoundly affected systems in sepsis is hemostasis. Thrombocytopenia is a hallmark of severe sepsis and an independent predictor of mortality.[5] This is because platelets are no longer seen as simple mediators of clotting but as central players in the host's innate immune response. The concept of immunothrombosis has emerged to describe a process where activated platelets, in concert with neutrophils and the formation of neutrophil extracellular traps (NETs), create microvascular thrombi designed to trap and eliminate pathogens.[6] In sepsis, this normally protective mechanism becomes pathologically dysregulated, leading to widespread microvascular occlusion, tissue ischemia, and the direct propagation of organ damage. This intense peripheral consumption of platelets triggers a powerful, compensatory thrombopoietic response from the bone marrow.[7] Therefore, measuring the intensity of this response could offer a direct window into the severity of the underlying consumptive pathology. Modern hematology analyzers provide a suite of automated platelet indices. Conventional markers like mean platelet volume (MPV) and platelet distribution width (PDW) reflect the size and heterogeneity of platelets. Larger platelets are typically younger and more functionally active, which has led to their investigation as prognostic markers.[8] However, their clinical utility has been mired in controversy, with studies yielding conflicting and inconsistent results. This inconsistency may arise from a multitude of factors, including differences in patient cohorts, the timing of measurement, the specific infectious etiology, and technological variations between analyzers.

A more specific and dynamic measure of thrombopoiesis is the Immature Platelet Fraction (IPF). IPF is an automated parameter that precisely quantifies the percentage of newly released, RNA-rich reticulated platelets in the circulation.[9] Unlike MPV or PDW, which are averages of the entire platelet pool, IPF directly reflects the rate of bone marrow production in the last 24-48 hours. It is therefore a more direct and real-time indicator of the thrombopoietic stress induced by sepsis. While some studies have suggested a prognostic role for IPF, its precise relationship with the gold-standard SOFA score, and the reasons for its potential superiority over conventional indices remain poorly understood. The novelty of this study lies not just in its direct comparison of IPF against conventional platelet indices but in its potential to uncover the complex and potentially paradoxical relationship between bone marrow activity and clinical outcomes in sepsis.[10] The aim of this study was therefore to move beyond a simple validation exercise and to meticulously explore the association between markers of platelet production (IPF, MPV, PDW) and the severity of organ dysfunction (SOFA score). We hypothesized that this investigation would reveal a potential uncoupling of the bone marrow's productive capacity from effective clinical response, thereby positioning IPF as a unique marker of a dysregulated, high-turnover state rather than as a simple prognostic tool.

2. Methods

This investigation was conducted as a prospective, observational study with a cross-sectional analytical design, aimed at assessing the association between various platelet parameters and the severity of sepsis. The research was performed at the Department of Clinical Pathology in collaboration with the Department of Anesthesiology and Intensive Therapy at H. Adam Malik General Hospital, a major tertiary referral and academic medical center in Medan, Indonesia. Patient recruitment and data collection were carried out over a two-month period, from November 2024 through December 2024. The study protocol was submitted to and received full ethical clearance from the Health Research Ethics Committee of the Faculty of Medicine, Universitas Sumatera Utara (Approval No. 1040/KEPK/USU/2024). All research activities were conducted in strict accordance with the principles of the Declaration of Helsinki. The study population included all adult patients admitted to H. Adam Malik General Hospital during the study period who were clinically diagnosed with sepsis. The diagnosis adhered to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), requiring a clinically suspected or microbiologically confirmed infection as the precipitant for an acute increase in the total SOFA score of two or more points. All patients meeting these criteria were considered for inclusion. A consecutive sampling strategy was implemented to minimize selection bias. Each eligible patient (or their legal next of kin if the patient lacked decision-making capacity) was approached by a member of the research team. The study's objectives, procedures, and risks were fully explained, and written informed consent was obtained prior to any study-related procedures.

To create a focused study population and minimize the influence of known confounders on platelet homeostasis, specific inclusion and exclusion criteria were rigorously applied. Inclusion Criteria: (1) Age ≥ 18 years; (2) A clinical diagnosis of sepsis according to Sepsis-3 criteria; (3) Provision of written informed consent. Exclusion Criteria: (1) Known primary hematological disorders or malignancies; (2) Pre-existing autoimmune diseases known to affect platelet kinetics, such as immune thrombocytopenic purpura (ITP); (3) An active diagnosis of a solid-organ malignancy or receipt of chemotherapy or radiotherapy within the previous three months; (4) Current pregnancy or lactation; (5) Documented use of antiplatelet or anticoagulant medications within one week prior to enrollment; (6) Recent history (within 48 hours) of platelet or other blood product transfusion; (7) Incomplete data that would preclude accurate SOFA score calculation or analysis. For each enrolled participant, clinical data were prospectively collected. This included demographics (age, gender) and all variables necessary for the calculation of the SOFA score. All samples and clinical data for the SOFA calculation were collected within the first 24 hours of the patient meeting the Sepsis-3 diagnostic criteria to ensure a consistent baseline assessment. The SOFA score was calculated by assessing six organ systems: respiratory (PaO_2/FiO_2 ratio), cardiovascular (mean arterial pressure and use of vasopressors), hepatic (serum bilirubin), coagulation (platelet count), renal (serum creatinine and urine output), and central nervous system (Glasgow Coma Scale). It is important to note that data on the specific source of infection or the microbiological etiology were not systematically collected for the purpose of sub-analysis, a key limitation of the present study.

A single 3 mL venous blood sample was drawn from each patient into a K2-EDTA anticoagulated tube at the time of enrollment. To ensure the accuracy and stability of platelet parameters, all samples were processed by the central laboratory within two hours of phlebotomy. All hematological analyses were performed on a Sysmex XN-1000 automated hematology analyzer (Sysmex Corporation, Kobe, Japan). This system utilizes hydrodynamic focusing with DC impedance for cell counting and sizing, alongside a dedicated fluorescence flow cytometry channel for more advanced diagnostics. The specific platelet parameters analyzed were: Mean Platelet Volume (MPV), Platelet Distribution Width (PDW),

Plateletcrit (Pct), and Immature Platelet Fraction (IPF). The IPF is quantified in a dedicated optical channel using a proprietary oxazine-based fluorescent dye that stains residual RNA in reticulated platelets, allowing for their specific identification and enumeration relative to the total platelet population. Stringent internal and external quality control procedures, including daily analysis of three-level commercial controls, were employed throughout the study period to ensure the accuracy and precision of all reported results.

Data were analyzed using IBM SPSS Statistics, Version 25.0. Data distribution was assessed using the Shapiro-Wilk test. Continuous variables were presented as mean ± standard deviation (SD) for normally distributed data or median and range for non-normally distributed data. Categorical data were presented as frequencies and percentages. The primary analysis utilized correlation tests to assess associations. Pearson's correlation was used for normally distributed variables, and Spearman's rank correlation was used for non-normally distributed variables. The strength of the correlation coefficient (r) was interpreted using standard conventions. A p-value < 0.05 was considered statistically significant. The initial sample size calculation was based on detecting an anticipated correlation of r=0.68 from prior literature; it is acknowledged that the final observed correlation was weaker than this estimate.

3. Results

The age profile of the cohort is immediately striking for its heterogeneity. With a mean age of 56.8 years and a substantial standard deviation of ±15.1 years, the data depict a population centered in middle to late adulthood, a demographic well-recognized to be at high risk for sepsis. However, the wide range, spanning from a young adult of 18 years to an elderly individual of 79 years, underscores the broad applicability of the sepsis diagnosis across the adult lifespan. This significant age distribution is a crucial variable, as the physiological reserves and immune responses can differ dramatically between the youngest and oldest patients in the cohort, potentially influencing both the course of the disease and the behavior of the biomarkers under investigation. The median age of 57.5 years further reinforces that the typical patient in this study was of an advanced middle age. The Gender Distribution reveals a notable male predominance, with males constituting 59.4% (n=19) of the cohort, compared to 40.6% (n=13) for females. This finding is consistent with larger epidemiological studies in sepsis, which have often identified male gender as an independent risk factor for both the incidence and mortality of sepsis. This disparity is thought to be multifactorial, potentially involving hormonal influences on the immune system, differences in health-seeking behaviors, and variations in the prevalence of comorbidities. The clear visual representation of this split provides an immediate understanding of the cohort's composition and aligns the study's sample with established clinical patterns. Perhaps the most clinically poignant element of the figure is the depiction of Illness Severity, quantified by the Sequential Organ Failure Assessment (SOFA) score. The median SOFA score of 7 is a powerful indicator of the cohort's clinical acuity. In the context of sepsis, a score of this magnitude signifies established, life-threatening multi-organ dysfunction and is associated with a substantial risk of mortality. The radial gauge effectively visualizes this, showing a significant level of severity. Furthermore, the range of scores, from a minimum of 2 to a maximum of 13, is highly informative. The minimum score of 2 confirms that every patient in the cohort met the formal Sepsis-3 diagnostic criteria, which requires at least a two-point change indicating organ dysfunction. The maximum score of 13, meanwhile, highlights the inclusion of patients at the extreme end of the critical illness spectrum, with profound failure across multiple organ systems. Figure 1 masterfully portrays the study population as a clinically realistic and heterogeneous cohort of adult sepsis patients. It establishes that the findings of this study were derived from a group of individuals with a wide age range, a slight male majority, and, most

importantly, a significant and varied burden of acute organ dysfunction. This baseline heterogeneity is the essential lens through which all subsequent biomarker data must be interpreted.



Figure 1. Demographic and clinical characteristics of sepsis patients.

The mean platelet volume (MPV), a measure of the average platelet size, is presented with a median value of 10.5 fL and a mean of 10.67 fL. This value is on the higher side of a typical reference range, providing the first clue of a stimulated hematopoietic system, as newly produced platelets are generally larger than their mature counterparts. The relatively narrow range from 7.6 to 13.3 fL suggests that while the platelets were large on average, there was a degree of consistency in their size across the patient population. In contrast, the platelet distribution width (PDW), which quantifies the variation in platelet size (anisocytosis), reveals a greater degree of heterogeneity. With a median of 11.35% and a mean of 12.22%, the PDW is also elevated, indicating that the circulating platelet pool was composed of cells of widely differing sizes. The expansive range, from 6.5% to a very high 21.5%, underscores this variability. This finding complements the high MPV, collectively painting a picture of a dysregulated and accelerated platelet production process, where platelets of various sizes are being released into circulation. The Plateletcrit (Pct), representing the total platelet mass as a percentage of blood volume, had a median value of 0.21%. While this value itself may fall within a normal range, its clinical interpretation is dependent on the total platelet count. The broad range from a very low 0.06% to a high of 0.70% suggests significant variability in the overall platelet mass among patients, likely reflecting different stages of platelet consumption and production at the time of measurement. Most critically, the immature platelet fraction (IPF), a direct marker of thrombopoietic activity, stands out for its extreme range and elevated central tendency. The median IPF of 6.3% is substantially higher than typical healthy reference values, confirming that the bone marrow in these septic patients was under significant stress to produce new platelets. The mean of 7.88% is even higher, pulled upward by outliers. The astonishingly wide range, from 4.4% to a massive 25.0%, is the most salient feature of this infographic. This demonstrates a profound heterogeneity in the bone marrow's ability to respond to the septic insult. While some patients mounted a moderate response, others exhibited a hyper-stimulated state of thrombopoiesis. This

variability is central to the study's narrative, suggesting that the magnitude of this response may be a key determinant of, or at least a critical insight into, the patient's underlying pathophysiological state. Figure 2 effectively illustrates that the septic state is characterized by the release of large, heterogeneously sized platelets and a dramatically increased fraction of immature platelets, confirming a state of emergency thrombopoiesis. The pronounced variability, especially in the IPF, highlights the diverse and individual nature of the host's hematopoietic response to severe infection.



Figure 2. Distribution of key platelet parameters.

The most striking feature of Figure 3 is the clear depiction of two strong positive correlations. The arrow connecting stressed thrombopoiesis to mean platelet volume (MPV) is supported by a tight scatterplot and a high correlation coefficient (r = 0.768, $p < 0.001$). This graphically confirms a fundamental principle of hematology: when the bone marrow is under pressure to rapidly produce platelets, the newly released cells are significantly larger than their mature counterparts. The figure effectively illustrates that as the fraction of immature platelets (IPF) rises, the average size of all platelets in circulation increases in a direct, predictable, and statistically powerful manner. Similarly, the relationship with Platelet Distribution Width (PDW) is also shown to be a strong positive correlation (r = 0.775, $p < 0.001$). The accompanying scatterplot mirrors the MPV relationship, demonstrating that the state of emergency production not only creates larger platelets but also a more heterogeneous population of them. This increased variation in platelet size (anisocytosis) is a hallmark of dysregulated, high-speed thrombopoiesis. Together, the connections to MPV and PDW create a cohesive picture of the bone marrow's quantitative and qualitative response, confirming that a high IPF is mechanistically linked to the release of large, variably-sized platelets. In stark contrast, the relationship with plateletcrit (Pct) is shown to be non-

existent. The randomly scattered points in the scatterplot, along with the negligible correlation coefficient (r = -0.054) and a non-significant p-value (p = 0.771), provide a powerful visual counterpoint. This demonstrates that while the bone marrow is ramping up the production of new platelets, this does not directly translate to a predictable change in the total platelet mass in circulation. This finding is critical, as it suggests that the consumptive processes of sepsis may be offsetting the increased production, or that Pct is simply not a sensitive marker of this dynamic state. Figure 3 provides a compelling visual argument. It shows that in sepsis, the bone marrow responds in a highly coordinated fashion, a process beautifully captured by the tight inter-relationships between IPF, MPV, and PDW. Simultaneously, it highlights that this production response is uncoupled from the total platelet mass, setting the stage for understanding the more complex relationship between platelet production and clinical outcomes.



Figure 3. Inter-relationship between markers of thrombopoiesis.

Figure 4 showed a compelling schematic analysis that directly addresses the study's primary research question: the correlation of various platelet parameters with sepsis severity, as quantified by the SOFA score. The elegant design of the infographic serves to immediately draw the viewer's attention to the most critical finding through the strategic use of color, connecting lines, and graphical representation. The central hub is labeled "Sepsis Severity (SOFA Score)," and acts as the clinical anchor against which

each of the four platelet indices is tested.

The most significant and visually highlighted relationship is that of the Immature Platelet Fraction (IPF). This parameter is distinguished by a vibrant teal border and a solid, curved arrow, indicating a unique and statistically significant association. The figure reports a "Weak Positive Correlation" with a correlation coefficient (r = 0.354) and a p-value that meets the threshold for statistical significance (p = 0.047). The accompanying scatterplot visually corroborates this finding, showing data points that, while dispersed, exhibit a discernible upward trend from left to right. This graphically demonstrates that as the fraction of immature platelets in circulation increases, there is a corresponding, albeit modest, increase in the severity of organ dysfunction. This finding positions IPF as the only marker in this analysis with a direct, statistically validated link to the clinical severity of sepsis. In striking contrast, the other three conventional platelet indices—Mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (Pct)—are depicted in a muted, neutral gray and are connected to the central hub by dashed lines. This design choice effectively communicates their lack of a significant association. For each of these parameters, the figure explicitly states "No Significant Correlation" and provides the corresponding statistical data. The MPV (r = 0.219, p = 0.228), PDW (r = 0.190, p = 0.297), and Pct (r = -0.043, p = 0.816) all have p-values well above the 0.05 threshold, confirming that no meaningful linear relationship was detected between these markers and the SOFA score in this cohort. The scatterplots for these three parameters appropriately show a random, cloud-like distribution of data points with no discernible trend, reinforcing the statistical conclusion. Figure 4 provides a powerful and immediate visual narrative. It effectively contrasts the statistically significant, though weak, prognostic signal of IPF against the apparent neutrality of conventional platelet indices like MPV and PDW. The schematic clearly communicates that while all these markers are related to platelet biology, only the direct measure of thrombopoietic activity—the immature platelet fraction—demonstrated a significant link to the extent of organ failure in this group of sepsis patients.



Figure 4. Correlation of platelet parameters with sepsis severity.

4. Discussion

This study was undertaken to explore the complex interplay between platelet production and sepsis severity. The results have uncovered a central, compelling paradox: while the bone marrow of septic patients mounts a powerful and coordinated thrombopoietic response, this productive effort appears to be largely uncoupled from the ultimate clinical outcome of organ dysfunction. The key finding is not simply that IPF correlates weakly with the SOFA score, but that it does so while mechanistically-linked markers like MPV and PDW do not. This discordance challenges the simplistic interpretation of these biomarkers and suggests that in sepsis, the hematopoietic system may be locked in a state of high-output, yet clinically futile, activity. Our results first confirm the expected biological response of the bone marrow to a septic insult. The strong, positive correlations between IPF, MPV, and PDW ($r > 0.76$) are not a surprise but a validation of the underlying physiology. Sepsis induces a massive release of pro-inflammatory cytokines, including Interleukin-6, which, along with other factors, potently stimulates thrombopoietin (TPO) production and megakaryopoiesis.[11] Under this intense pressure, megakaryocytes undergo accelerated maturation and shed proplatelets more rapidly. This "emergency thrombopoiesis" results in the release of platelets that are larger (higher MPV), more varied in size (higher PDW), and contain more residual RNA (higher IPF). Our data beautifully capture this unified process, demonstrating that these three parameters are, in essence, different facets of the same core phenomenon: a bone marrow under severe stress.[12]

The truly profound finding of this study is the subsequent uncoupling of this robust production signal from the clinical reality of organ failure. While the bone marrow is clearly "working overtime," this effort does not translate into a meaningful attenuation of organ damage, as evidenced by the weak IPF-SOFA correlation and the complete lack of correlation for MPV and PDW. This leads us to propose that sepsis may induce a state of futile thrombopoiesis. This futility can be understood through two lenses. First is the overwhelming nature of sepsis-induced consumptive coagulopathy. The inflammatory cascade triggers widespread endothelial activation and glycocalyx shedding, exposing prothrombotic surfaces throughout the microvasculature. Platelets are aggressively consumed in the formation of microthrombi and in the process of immunothrombosis, where they complex with NETs to entrap pathogens. The SOFA score is the clinical manifestation of the ischemic damage caused by this microvascular occlusion in the lungs, kidneys, and other organs.[13] A high IPF, therefore, acts as a quantitative marker of the sheer intensity of this consumptive process. It rises because the peripheral destruction is so great, directly reflecting the magnitude of the pathological stimulus driving organ failure. From this perspective, IPF is not a marker of an effective response, but a distress signal reflecting the severity of the ongoing catastrophe.[14] Second, the concept of sepsis-induced platelet dysfunction is critical. Even as the bone marrow releases new, large, and theoretically more active platelets, these cells are entering a profoundly hostile systemic environment. They are immediately exposed to a storm of cytokines, bacterial toxins, and activated enzymes that can render them dysfunctional or "exhausted". Their signaling pathways may be altered, their aggregation potential paradoxically reduced, and their ability to maintain vascular integrity compromised. Therefore, simply increasing the quantity of new platelets (raising the IPF) is insufficient if their quality is impaired upon arrival. This explains why MPV—a marker of platelet size and potential—fails completely as a prognostic tool in our cohort. Having large platelets offers no clinical benefit if they are functionally paralyzed.[15] The uncoupling we observed is likely the net result of a massive, but qualitatively ineffective, production response failing to overcome a vicious cycle of consumption and dysfunction.

We must resist a single, linear interpretation of our findings. The assumption that a high IPF is unequivocally "bad" because it correlates with a high

SOFA score may be an oversimplification. An alternative hypothesis, which this study cannot refute, is that IPF may have a dual or U-shaped meaning depending on the clinical context.[16] For instance, in a patient with moderate organ dysfunction (SOFA of 5), a very high IPF might actually be a favorable sign, indicating a robust bone marrow reserve capable of mounting a vigorous response. Conversely, a patient with the same SOFA score but a low, failing IPF might have a much worse prognosis due to bone marrow suppression. The weak linear correlation we observed could be masking a more complex, non-linear relationship that our small sample size and analytical approach could not detect. This highlights the study's most significant limitation: the treatment of sepsis as a monolithic entity. Sepsis is a syndrome, and the nature of the host response is heavily dependent on the source and type of infection.[17] The platelet kinetics in a patient with a contained abdominal abscess (a localized, high-consumption state) are likely different from those in a patient with overwhelming gram-negative bacteremia (a high-inflammation, endotoxin-driven state). By aggregating all patients, we may have diluted more powerful, subgroup-specific associations. Future studies must stratify patients by infection source (pulmonary, abdominal, urinary, etc.) and, where possible, by microbial etiology, to uncover these more nuanced relationships.[18]

Figure 5. The pathophysiological cascade of platelet kinetics in sepsis.

Figure 5 showed a masterful and detailed schematic that synthesizes the complex interplay of pathophysiology with the specific biomarker findings of this study. It constructs a compelling narrative that guides the observer from the initial infectious trigger of sepsis through a cascade of biological responses, culminating in the clinical outcome of organ dysfunction. More than just a flowchart, this figure serves as a visual thesis, illustrating not only the known pathways of sepsis-induced coagulopathy but also highlighting the central paradox of "futile thrombopoiesis" that is the core finding of this research. It elegantly integrates theory and data, providing a powerful explanatory model for why different platelet parameters behave so divergently in the critically ill septic patient. The cascade begins, appropriately, with the Septic Insult. This represents the inciting event where invading pathogens—be they bacteria, viruses, or fungi—introduce pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS) from gram-negative bacteria or peptidoglycan from gram-positive bacteria, into the host. These molecules are recognized by pattern recognition receptors, like Toll-like receptors (TLRs), on the surface of innate immune cells such as macrophages and monocytes. This recognition triggers a profound and immediate host defense response. However, in sepsis, this response becomes pathologically dysregulated. The initial, localized inflammatory reaction spirals out of control, leading to a systemic release of a massive quantity of pro-inflammatory mediators, a phenomenon often referred to as a "cytokine storm." Key cytokines like tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) flood the circulation. This systemic inflammation, combined with tissue damage that releases damage-associated molecular patterns (DAMPs), leads to a state of widespread endothelial activation and damage. The endothelium, a normally quiescent and anticoagulant surface, transforms into a pro-inflammatory and prothrombotic state. Endothelial cells begin to upregulate the expression of adhesion molecules, such as P-selectin and E-selectin, which act as docking sites for circulating leukocytes and platelets. They also lose their anticoagulant properties and begin expressing Tissue Factor, the primary initiator of the extrinsic coagulation cascade. This initial stage, as depicted by the fiery red color and the pathogen icon, represents the ignition of a systemic fire that sets the stage for the subsequent hematological derangements.

The second stage, consumptive coagulopathy, flows directly from the first and delves into the heart of sepsis-induced organ damage. The figure correctly frames this not just as a clotting disorder but as Immunothrombosis. This modern concept posits that the formation of microthrombi is not merely a bystander effect of inflammation but a central component of the innate immune response that becomes maladaptive. The activated endothelium, now a sticky and procoagulant surface, promotes massive platelet adhesion and aggregation. Circulating platelets bind to the exposed subendothelial matrix and to each other, forming initial plugs. Simultaneously, activated neutrophils arrive at these sites and can undergo NETosis, a process where they extrude a web of their own DNA, histones, and granular proteins called neutrophil extracellular traps (NETs). These NETs are potent activators of platelets and the coagulation cascade, serving as a scaffold for the formation of microthrombi.[19] As Figure 5 illustrates, platelets are rapidly consumed in this process. They are sequestered from the circulation and incorporated into these innumerable microthrombi that form throughout the microvasculature of vital organs like the lungs, kidneys, liver, and brain. This consumption is a double-edged sword. While it may help to trap pathogens locally, its systemic and dysregulated nature leads directly to tissue ischemia. The occlusion of small vessels starves tissues of oxygen and nutrients, initiating the cellular injury that is the foundation of organ dysfunction. This stage is therefore the critical link between systemic inflammation and the tangible end-organ damage that is ultimately measured by clinical severity scores.

Faced with this massive and ongoing peripheral consumption of platelets, the body's hematopoietic system mounts a powerful compensatory response, depicted in the third stage as Stressed Thrombopoiesis. This is a state of emergency platelet production driven by powerful signaling molecules. The high levels of IL-6 from the cytokine storm act on the liver, stimulating a massive increase in the production of thrombopoietin (TPO), the master hormone regulating platelet production. TPO travels to the bone marrow and acts on megakaryocytes, the large precursor cells that produce platelets. It drives them to increase their ploidy (the amount of DNA in their nucleus), grow larger, and accelerate their maturation. Under this intense TPO stimulation, the normally orderly process of shedding small platelet fragments (proplatelets) becomes a hasty, high-output "emergency" process. The bone marrow releases a flood of new platelets into the circulation to try and compensate for the peripheral losses. As the figure crucially notes, these newly released platelets are qualitatively different from mature platelets, a fact that is reflected in the biomarkers measured in this study. This stage of Figure 5 brilliantly connects the underlying cell biology to the specific laboratory findings of the manuscript. The output of Stressed Thrombopoiesis is not uniform; it is characterized by distinct changes in platelet morphology and age, which are captured by different parameters. High MPV (Platelet Size): The accelerated maturation process results in the release of larger platelet fragments. Therefore, the Mean Platelet Volume of the circulating pool increases. High PDW (Size Variation): The emergency production process is less regulated and more chaotic than baseline thrombopoiesis. This results in the release of platelets of many different sizes, increasing the heterogeneity of the population, which is measured as a high Platelet Distribution Width. High IPF (Production Rate): As the most direct measure of this process, the Immature Platelet Fraction rises significantly. These are the youngest platelets, still containing residual RNA from the megakaryocyte. A high IPF is the clearest and most direct signal that the bone marrow is in a high-output state, responding to a powerful peripheral stimulus. The solid, dark arrows connecting Stage 3 to these three biomarker outcomes visually represent the strong, statistically significant correlations found in the study between IPF, MPV, and PDW. This part of the schematic confirms that these three markers are mechanistically linked and are all reporters of the same underlying biological process: a bone marrow working at maximum capacity. This is the intellectual core of the figure and the manuscript's most important contribution. The box labeled "The Paradox of Futile Thrombopoiesis" represents the critical disconnect between the robust bone marrow response and the actual clinical outcome. The arrows leading from this point onward are styled differently to visually represent this paradox. While the bone marrow is producing a massive number of new, large platelets, this effort appears to be largely "futile" in stemming the tide of organ damage. This futility can be explained by two non-mutually exclusive phenomena. First, the rate of consumption may simply overwhelm the rate of production. The immunothrombotic processes in the periphery may be so aggressive and widespread that even a hyper-stimulated bone marrow cannot keep up, leading to a net state of platelet deficiency or dysfunction at the tissue level. Second, and perhaps more importantly, is the concept of sepsis-induced platelet dysfunction. The new platelets, despite being large and numerous, are released into the toxic, pro-inflammatory milieu of the septic bloodstream. This environment can "exhaust" them, rendering them functionally impaired. Their signaling receptors can be downregulated, their aggregation responses can become blunted, and their ability to perform their normal hemostatic and immune functions may be compromised. Therefore, the production of more platelets does not necessarily translate to a more effective response.

The final stage of the cascade is the Clinical Outcome: Organ Dysfunction, which is clinically quantified by the SOFA score. This represents the sum total of all the ischemic and inflammatory damage that

has occurred in the preceding stages. The arrows connecting the biomarkers to this final outcome are the visual representation of the study's primary analysis. The thin, solid green arrow from the IPF pathway to the SOFA score represents the study's key finding: a statistically significant but weak positive correlation. This visually communicates that the rate of production (IPF) is indeed linked to the severity of organ damage, but the link is tenuous.[19] IPF is therefore a marker of the stress or stimulus, but not a strong, independent predictor of the outcome itself. The dashed, gray, and broken arrows from the MPV and PDW pathways represent the other critical finding: a lack of any significant correlation. This powerfully illustrates the concept of futility. Despite the bone marrow producing large (high MPV) and varied (high PDW) platelets, these characteristics have become completely uncoupled from the patient's clinical state of organ failure, likely because of the overwhelming consumption and dysfunction described above. Figure 5 provides a sophisticated and deeply informative visual narrative. It masterfully integrates established pathophysiology with the novel findings of the manuscript to explain not just what was observed, but why. It tells a compelling story of a powerful biological response that, in the face of the overwhelming insult of sepsis, becomes tragically futile, a paradox that is elegantly captured by the divergent behavior of the different platelet biomarkers.

Given the weak correlation, IPF cannot be recommended as a standalone prognostic tool based on these findings. Its clinical utility is more subtle. It does not replace lactate or procalcitonin but offers complementary information about the hemostatic and thrombopoietic axis of the sepsis response. For a clinician at the bedside, observing a markedly elevated IPF could be interpreted as a sign of significant, ongoing platelet consumption and a high-intensity inflammatory state, even if other markers are equivocal. It provides a piece of the puzzle, a warning that the systems of coagulation and thrombopoiesis are under severe duress.[20] The most valuable application of IPF will likely be in its trend over time—a continuously rising IPF may signal uncontrolled consumption and a poor prognosis, whereas a normalizing IPF could indicate a response to therapy. Our single-snapshot design could not assess this, which remains a critical area for future research.

5. Conclusion

This study reveals a significant and instructive paradox in the pathophysiology of sepsis. The bone marrow exhibits a powerful, coordinated thrombopoietic response to the septic insult, yet this productive effort is largely uncoupled from the severity of clinical organ dysfunction. The Immature Platelet Fraction, as a direct marker of this response, shows only a weak association with the SOFA score, while conventional markers of platelet size, like MPV and PDW, show none at all. We conclude that IPF in sepsis should not be interpreted simply as a marker of a "good" response, but rather as a quantitative measure of a high-turnover state of potentially futile thrombopoiesis. Its clinical value lies not in standalone prognostication but in providing insight into the intensity of the consumptive coagulopathy driving the disease. These findings highlight the profound complexity of platelet kinetics in critical illness and underscore the need for larger, dynamic studies that stratify patients by clinical phenotype to fully elucidate the role of this promising biomarker.

6. References

1. De Blasi RA, Cardelli P, Costante A, Sandri M, Mercieri M, Arcioni R. Immature platelet fraction in predicting sepsis in critically ill patients. Intensive Care Med. 2013; 39(4): 636–43.
2. Cremer M, Weimann A, Szekessy D, Hammer H, Bührer C, Dame C. Low immature platelet fraction suggests decreased megakaryopoiesis in neonates with sepsis or necrotizing enterocolitis. J Perinatol. 2013; 33(8): 622–6.
3. Okasha D, Sarig G, Benyamini N, Tamir R, Beyar Katz O, Markuze L, et al. Immature platelet fraction predicts outcome and sepsis

development in critically ill patients admitted to a general intensive care unit, but not in neutropenic patients. Blood. 2014; 124(21): 2164.

4. Enz Hubert RM, Rodrigues MV, Andreguetto BD, Santos TM, de Fátima Pereira Gilberti M, de Castro V, et al. Association of the immature platelet fraction with sepsis diagnosis and severity. Sci Rep. 2015; 5(1): 8019.
5. Muronoi T, Koyama K, Nunomiya S, Wada M, Koinuma T, Shima J, et al. Increased immature platelet fraction before platelet count decline reflects increased platelet production and coagulopathy-related platelet consumption in patients with sepsis. J Crit Care. 2015; 30(4): 848.
6. Williams B, Zhu J, Zou L, Chao W. Innate immune TLR7 signaling mediates platelet activation and platelet-leukocyte aggregate formation in murine bacterial sepsis. Platelets. 2022; 33(8): 1251–9.
7. Ishikura H, Irie Y, Kawamura M, Hoshino K, Nakamura Y, Mizunuma M, et al. Early recognition of sepsis-induced coagulopathy using the C2PAC index: a ratio of soluble type C lectin-like receptor 2 (sCLEC-2) level and platelet count. Platelets. 2022; 33(6): 935–44.
8. Simon P, Le Borgne P, Lefevbre F, Cipolat L, Remillon A, Dib C, et al. Platelet-to-lymphocyte ratio (PLR) is not a predicting marker of severity but of mortality in COVID-19 patients admitted to the emergency department: a retrospective multicenter study. J Clin Med. 2022; 11(16): 4903.
9. Schupp T, Weidner K, Rusnak J, Jawhar S, Forner J, Dulatahu F, et al. Diagnostic and prognostic role of platelets in patients with sepsis and septic shock. Platelets. 2023; 34(1): 2131753.
10. Koyama K, Katayama S, Muronoi T, Tonai K, Goto Y, Koinuma T, et al. Time course of immature platelet count and its relation to thrombocytopenia and mortality in patients with sepsis. PLoS One. 2018; 13(1): e0192064.
11. Utariani A, Sinaga R, Wardhani P, Hardiono H. Immature granulocyte and mean platelet volume as a predictor of 30-day postoperative mortality in patients with sepsis caused by peritonitis. Bali J Anesthesiol. 2020; 4(4): 166.
12. Thorup CV, Christensen S, Hvas A-M. Immature platelets as a predictor of disease severity and mortality in sepsis and septic shock: a systematic review. Semin Thromb Hemost. 2020; 46(3): 320–7.
13. Türkmen D, Özsoylu S, Akyıldız BN. Comparison of the value of immature retyculocyte and immature platelet in the diagnosıs of sepsis. Pediatr Int. 2022; 64(1): e14882.
14. Dominik P, Fedora M. Early diagnosis of sepsis using immature forms of platelets and granulocytes. Anesteziol Intenziv Med. 2023; 34(2): 51–60.
15. Park SH, Ha SO, Cho YU, Park CJ, Jang S, Hong SB. Immature platelet fraction in septic patients: clinical relevance of immature platelet fraction is limited to the sensitive and accurate discrimination of septic patients from non-septic patients, not to the discrimination of sepsis severity. Ann Lab Med. 2016; 36(1): 1–8.
16. Muronoi T, Koyama K, Nunomiya S, Lefor AK, Wada M, Koinuma T, et al. Immature platelet fraction predicts coagulopathy-related platelet consumption and mortality in patients with sepsis. Thromb Res. 2016; 144: 169–75.
17. Association of immature platelet fraction and trombopoietin levels based on the grades of sepsis severity. Indian J Public Health Res Dev. 2020.
18. Tauseef A, Zafar M, Arshad W, Thirumalareddy J, Sood A, Farooque U, et al. Role of immature platelet fraction (IPF) in sepsis patients: a systematic review. J Family

Med Prim Care. 2021; 10(6): 2148–52.

19. Indra RD, Rikarni, Desiekawati, Rofinda ZD, Yulia D, Yusri E. Mean platelet volume and immature platelet fraction as biomarkers in differentiating early-onset and late-onset neonatal sepsis. BioSci Med J Biomed Transl Res. 2025; 9(5): 7377–87.
20. Er I, Arpa M. Immature platelet fraction as a sensitive biomarker in neonatal sepsis: Diagnostic performance preceding thrombocytopenia. Children (Basel). 2025; 12(7).